Form 4: Spruce Biosciences CEO Acquires Shares

Javier B. Szwarcberg, CEO of Spruce Biosciences, Inc., acquired 266 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Javier B. Szwarcberg, Chief Executive Officer and Director of Spruce Biosciences, Inc. (SPRB), acquired 266 shares of common stock.
• The acquisition occurred on June 30, 2026, at a price of $4.5305 per share.
• These shares were purchased under the Issuer's 2020 Employee Stock Purchase Plan.
• The transaction is exempt under Rule 16b-3(d) and Rule 16b-3(c).
• Following this transaction, Szwarcberg beneficially owns 19,270 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates continued investment by the CEO in the company's stock through a standard employee plan.

Positives

• Insider buying activity, with the CEO acquiring more shares, can be seen as a positive signal of confidence in the company's future prospects.
• The acquisition was made through an Employee Stock Purchase Plan, indicating a structured and ongoing investment by management.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider transactions, particularly purchases by senior management, are closely watched by investors as potential indicators of management's belief in the company's valuation and future performance within the biotechnology sector.

Stakeholder Impact

• Shareholders may view this as a positive signal of management's confidence in the company's stock.
• Employees participating in the Employee Stock Purchase Plan are engaging in a structured method of equity ownership.

Key Dates

Keywords

Spruce Biosciences, SPRB, Form 4, Insider Trading, Stock Purchase Plan, CEO, Director, Common Stock, Beneficial Ownership